Jaimy Lee is a deputy editor at Endpoints. With over 15 years of experience, she specializes in covering pharmaceuticals, the business of healthcare, and related topics such as the FDA and the Coronavirus, including significant coverage of Moderna and Pfizer. Jaimy's work has been featured in MarketWatch, Yahoo Finance, and Endpoints News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Not enough data
Jaimy Lee's coverage focuses on healthcare and pharmaceuticals, with a significant emphasis on investment analysis and private sector announcements. Given the nature of her articles, she is likely to be receptive to pitches from individuals or organizations involved in drug development, biotech partnerships, or financing within the healthcare and pharmaceutical industries.
Her focus on press releases and citing data indicates that she values accuracy and official information. Pitches should highlight well-supported facts relevant to the topics covered such as new drug developments, business collaborations, or financial trends specific to the healthcare sector.
While Jaimy Lee does not specify a geographic focus in her article titles, it is important for potential sources reaching out to consider her coverage spans international markets within the healthcare and pharmaceutical sectors.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Jaimy Lee
Milestone Pharmaceuticals details plan to resubmit etripamil to the FDA in Q2: For its experimental treatment for paroxysmal supraventricular
By: Jaimy Lee
Plus, news about Xencor, Otsuka, Typewriter Therapeutics, Cassava Sciences, Enveric Biosciences, Viking Therapeutics and Janux Therapeutics:
By: Jaimy Lee
Plus, news about Tarsus Pharmaceuticals, Humacyte, Stemcell Technologies and SQZ Biotechnologies:
Plus, news about Iovance Biotherapeutics, Nektar Therapeutics, Heidelberg Pharma, Vivoryon Therapeutics and Absci:
By: Ayisha Sharma, Jaimy Lee
Plus, news about Telios Pharma and Celldex Therapeutics: Another day, another public offering: Apogee Therapeutics is aiming to raise $350
Plus, news about Aquestive Therapeutics and Cybin: AbbVie enlists Parvus Therapeutics for IBD pact: AbbVie will have the option to develop
The FDA rejected Applied Therapeutics' experimental treatment for a rare disease called classic galactosemia, citing deficiencies with the application.
(833) 317-6278 
